Market Overview

Botox Competition Spurs Argus To Downgrade Allergan

Botox Competition Spurs Argus To Downgrade Allergan
Related AGN
The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio
Earnings Scheduled For October 30, 2018
Teva up 1% premarket on positive fremanezumab data (Seeking Alpha)

Shares of Allergan plc Ordinary Shares (NYSE: AGN) continue trading near their multi year low of $160.07, with many investors concerned with a competitive environment that will intensify in the coming years.

The Analyst

Argus' David Toung downgraded Allergan's stock rating from Buy to Hold.

The Thesis

Allergan will see two of its major products, Botox and Restasis, face major competition, which justifies a reduction in the stock's rating, Toung said in the downgrade note. (See Toung's track record here.)

Botox will likely compete with what is considered to be a "better Botox" alternative by Revance Therapeutics Inc (NASDAQ: RVNC) called RT002, Toung said. And the dry eye treatment Restasis will likely see generic competition by the middle of next year after a U.S. District Court invalidated the company's patents.

Botox accounted for $2.79 billion of Allergan's 2016 revenue and demonstrated a double-digit growth rate in the third quarter of 2017, the analyst said. Allergan took a $3.2-billion asset impairment charge in the third quarter to better reflect the write-down of the patent assets.

Allergan does have some late-stage data readouts due to be released next year which could improve investor sentiment, Toung said. The company could also offset Restaiss losses through new products and assets via acquisitions, the analyst said.

Price Action

Shares of Allergan were trading lower by more than 2 percent Thursday morning and are down nearly 22 percent since the start of 2017.

Related Links:

Analyst Says Negative Allergan Headlines Are Priced In, Upgrades Stock

Imprimis Launches 99-Cent Generic Drug To Compete With Allergan's Restasis

Latest Ratings for AGN

Nov 2018Leerink SwannInitiates Coverage OnOutperform
Oct 2018Credit SuisseMaintainsOutperformOutperform
Oct 2018Raymond JamesMaintainsOutperformOutperform

View More Analyst Ratings for AGN
View the Latest Analyst Ratings

Posted-In: Argus BOTOX David ToungAnalyst Color Downgrades Health Care Analyst Ratings General Best of Benzinga


Related Articles (AGN + RVNC)

View Comments and Join the Discussion!

Latest Ratings

CEQPGoldman SachsUpgrades43.0
CLXTGoldman SachsUpgrades18.0
EQMGoldman SachsDowngrades49.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

31 Stocks Moving In Thursday's Mid-Day Session

Why Fannie And Freddie Have A Path To Survival